Top Markets
#1 Wrapped One Wrapped One +14,737.38%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +2,972.21%
#3 DeFi Kingdoms DeFi Kingdoms +1,091.71%
#4 Black Phoenix Black Phoenix +335.18%
#5 aPriori aPriori +117.19%
#6 Bedrock Bedrock +73.92%
#7 Cysic Cysic +44.55%
#8 Prom Prom +42.47%
#9 Playnance Playnance +34.34%
#10 COTI COTI +33.81%
Coin of the day
Wrapped One Wrapped One
Settings
Language
ENGLISH
Currency
USD
Theme
Kaleido Biosciences, Inc. Kaleido Biosciences, Inc.

Kaleido Biosciences, Inc.

KLDO
Rank in Stocks #42678
Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to... Kaleido Biosciences, Inc. is a clinical-stage healthcare firm dedicated to pioneering microbiome metabolic therapies. Its pipeline includes specific drug candidates such as KB195 for urea cycle disorders, KB295 targeting ulcerative colitis, KB174 aimed at hepatic encephalopathy, and KB109 for COVID-19. The company is also advancing programs in other significant therapeutic areas, including multi-drug resistant infections, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and various inflammatory bowel conditions. Kaleido maintains strategic collaborations with Institute Gustave Roussy, Washington University, and Janssen. Established in 2015, its headquarters are situated in Lexington, Massachusetts.
Share Price
$0.00001
Last synced: 2026-07-30
Market Cap
$426.00
Change (1 day)
0.00%
Change (1 year)
-90.00%
Country
US
Trade Kaleido Biosciences, Inc. (KLDO)

Category

Healthcare
Earnings for Kaleido Biosciences, Inc. (KLDO)
Earnings in 2026 TTM: 0
According to Kaleido Biosciences, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Kaleido Biosciences, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR